Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0E3SH
|
||||
| Former ID |
DCL000914
|
||||
| Drug Name |
Panobinostat
|
||||
| Synonyms |
Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Multiple myeloma [ICD9: 140-199, 203.0, 210-229; ICD10:C90] | Approved | [556264] | ||
| Type 2 diabetes [ICD9: 250; ICD10:E11] | Phase 3 | [532695], [542511] | |||
| Primary myelofibrosis; Post-polycythemia vera; Post-essential thrombocytopenia; Cutaneous T cell-lymphomas [ICD9: 203.0, 287.3, 287.4, 287.5, 289.0, 289.83, 776.4; ICD10:C90.0, C94.4, D47.1, D69.6, D75.1, P61.0, P61.1] | Phase 2 | [537114], [542511] | |||
| Company |
Novartis
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H23N3O2
|
||||
| InChI |
InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+
|
||||
| InChIKey |
FPOHNWQLNRZRFC-ZHACJKMWSA-N
|
||||
| CAS Number |
CAS 404950-80-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
12015928, 15274143, 17195129, 43530200, 57372035, 62645030, 75710455, 81055018, 87226499, 87350378, 93300558, 99436947, 103632713, 109693246, 114788640, 118049495, 123051106, 124756947, 125163753, 126657606, 126666979, 126731350, 127342240, 127342241, 131404644, 131465111, 134339363, 134964365, 135252712, 136340102, 136345863, 136367899, 136379865, 136920346, 137003312, 140114795, 143497586, 144116133, 152212116, 152237701, 152258137, 152344186, 160646976, 162011828, 162037392, 162193612, 163312349, 164194122, 164825246, 172086282
|
||||
| Target and Pathway | |||||
| Target(s) | Histone deacetylase 1 | Target Info | Inhibitor | [536272], [536509], [536739], [537647] | |
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Wnt signaling pathway | ||||
| p53 pathway | |||||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
| Notch signaling pathway | |||||
| E2F transcription factor network | |||||
| Presenilin action in Notch and Wnt signaling | |||||
| Signaling events mediated by HDAC Class I | |||||
| Regulation of Telomerase | |||||
| Glucocorticoid receptor regulatory network | |||||
| Sumoylation by RanBP2 regulates transcriptional repression | |||||
| Regulation of Androgen receptor activity | |||||
| IL3-mediated signaling events | |||||
| Validated nuclear estrogen receptor alpha network | |||||
| Retinoic acid receptors-mediated signaling | |||||
| Hedgehog signaling events mediated by Gli proteins | |||||
| Regulation of nuclear beta catenin signaling and target gene transcription | |||||
| Validated targets of C-MYC transcriptional repression | |||||
| Regulation of retinoblastoma protein | |||||
| Notch-mediated HES/HEY network | |||||
| Reactome | G0 and Early G1 | ||||
| p75NTR negatively regulates cell cycle via SC1 | |||||
| Formation of the beta-catenin:TCF transactivating complex | |||||
| NOTCH1 Intracellular Domain Regulates Transcription | |||||
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | |||||
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | |||||
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | |||||
| HDACs deacetylate histones | |||||
| Deactivation of the beta-catenin transactivating complex | |||||
| NoRC negatively regulates rRNA expression | |||||
| RNA Polymerase I Transcription Initiation | |||||
| Factors involved in megakaryocyte development and platelet production | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Notch Signaling Pathway | |||||
| TGF beta Signaling Pathway | |||||
| IL-6 signaling pathway | |||||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | |||||
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | |||||
| Notch Signaling Pathway | |||||
| Retinoblastoma (RB) in Cancer | |||||
| Neural Crest Differentiation | |||||
| TWEAK Signaling Pathway | |||||
| Integrated Breast Cancer Pathway | |||||
| Signalling by NGF | |||||
| RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription | |||||
| Mitotic G1-G1/S phases | |||||
| Factors involved in megakaryocyte development and platelet production | |||||
| Cell Cycle | |||||
| Androgen receptor signaling pathway | |||||
| References | |||||
| Ref 532695 | Progress of HDAC inhibitor panobinostat in the treatment of cancer. Curr Drug Targets. 2014 Jun;15(6):622-34. | ||||
| Ref 537114 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | ||||
| Ref 542511 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7489). | ||||
| Ref 556264 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
| Ref 536272 | Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. | ||||
| Ref 536509 | Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. | ||||
| Ref 536739 | Emerging drugs in cutaneous T cell lymphoma. Expert Opin Emerg Drugs. 2008 Jun;13(2):345-61. | ||||
| Ref 537647 | Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.